Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Edwards Lifesciences Corporation or Smith & Nephew plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Edwards Lifesciences Corporation and Smith & Nephew plc compare based on key financial metrics to determine which better meets your investment needs.

About Edwards Lifesciences Corporation and Smith & Nephew plc

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Latest Health Care Equipment & Supplies and Edwards Lifesciences Corporation, Smith & Nephew plc Stock News

As of July 30, 2026, Edwards Lifesciences Corporation had a $50.0 billion market capitalization, compared to the Health Care Equipment & Supplies median of $334.8 million. Edwards Lifesciences Corporation’s stock is up 1% in 2026, up 4.2% in the previous five trading days and up 8.02% in the past year.

Currently, Edwards Lifesciences Corporation’s price-earnings ratio is 47.1. Edwards Lifesciences Corporation’s trailing 12-month revenue is $6.3 billion with a 15.4% net profit margin. Year-over-year quarterly sales growth most recently was 16.7%. Analysts expect adjusted earnings to reach $2.998 per share for the current fiscal year. Edwards Lifesciences Corporation does not currently pay a dividend.

As of July 30, 2026, Smith & Nephew plc had a $13.3 billion market cap, putting it in the 81st percentile of all stocks. Smith & Nephew plc’s stock is down 3.8% in 2026, up 3.2% in the previous five trading days and up 2.31% in the past year.

Currently, Smith & Nephew plc’s price-earnings ratio is 45.2. Smith & Nephew plc’s trailing 12-month revenue is $6.2 billion with a 10.1% net profit margin. Year-over-year quarterly sales growth most recently was 7.4%. There are no analysts providing consensus earnings estimates for the current fiscal year. Smith & Nephew plc currently has a 3.0% dividend yield.

How We Compare Edwards Lifesciences Corporation and Smith & Nephew plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Edwards Lifesciences Corporation and Smith & Nephew plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Edwards Lifesciences Corporation and Smith & Nephew plc Stock Value Grades

Company	Ticker	Value
Edwards Lifesciences Corporation	EW	F
Smith & Nephew plc	SNN	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Edwards Lifesciences Corporation has a Value Score of 14, which is Ultra Expensive. Smith & Nephew plc has a Value Score of 27, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Edwards Lifesciences Corporation or Smith & Nephew plc has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Edwards Lifesciences Corporation or Smith & Nephew plc is the better investment when it comes to value.

Edwards Lifesciences Corporation and Smith & Nephew plc’s Momentum Grades

Company	Ticker	Momentum
Edwards Lifesciences Corporation	EW	C
Smith & Nephew plc	SNN	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Edwards Lifesciences Corporation has a Momentum Score of 46, which is Average. Smith & Nephew plc has a Momentum Score of 45, which is Average.

The Momentum Stock Winner: No Clear Winner

Neither Edwards Lifesciences Corporation or Smith & Nephew plc has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Edwards Lifesciences Corporation or Smith & Nephew plc is the better investment when it comes to momentum.

Edwards Lifesciences Corporation and Smith & Nephew plc’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Edwards Lifesciences Corporation	EW	C
Smith & Nephew plc	SNN	na

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Edwards Lifesciences Corporation has a Earnings Estimate Score of 57, which is Neutral. Smith & Nephew plc does not have a meaningful Earnings Estimate Score.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Edwards Lifesciences Corporation or Smith & Nephew plc has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Edwards Lifesciences Corporation or Smith & Nephew plc is the better investment when it comes to estimate revisions.

Other Edwards Lifesciences Corporation and Smith & Nephew plc Grades

In addition to Momentum, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Edwards Lifesciences Corporation and Smith & Nephew plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Edwards Lifesciences Corporation or Smith & Nephew plc Stock?

Overall, Edwards Lifesciences Corporation stock has a Value Score of 14, Momentum Score of 46 and Estimate Revisions Score of 57.

Smith & Nephew plc stock has a Value Score of 27, Momentum Score of 45 and Estimate Revisions Score of .

Comparing Edwards Lifesciences Corporation and Smith & Nephew plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.